SCHEMBL10122962

SCHEMBL10122962

Cc1cc(Nc2cc(C(=O)NCCN3CCOCC3)nc(/C=C/c3cccc(NC(=O)C4CC4)c3)n2)n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 12/20 0.49
AURKB Q96GD4 9/20 0.49
RIPK1 Q13546 5/20 0.49
IGF1R P08069 2/20 0.45
AURKC Q9UQB9 2/20 0.43
RET P07949 4/20 0.42
PLK4 O00444 3/20 0.42
ABL1 P00519 3/20 0.42
NTRK1 P04629 3/20 0.42
LCK P06239 3/20 0.42
CSF1R P07333 3/20 0.42
KIT P10721 3/20 0.42
FGFR1 P11362 3/20 0.42
SRC P12931 3/20 0.42
PDGFRA P16234 3/20 0.42
TYK2 P29597 3/20 0.42
KDR P35968 3/20 0.42
FLT3 P36888 3/20 0.42
MAP4K5 Q9Y4K4 3/20 0.42
PTK2 Q05397 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10122960 0.88 AURKA (0.54) AURKAAURKBIGF1RRETPLK4
SCHEMBL16660290 0.85 DYRK1A (0.41) IGF1RTYK2DYRK1AJAK1TGFBR1
SCHEMBL10122991 0.85 AURKA (0.49) AURKAAURKBIGF1RRETPLK4
SCHEMBL10123002 0.83 AURKA (0.48) AURKAAURKBIGF1RRETPLK4
SCHEMBL10123026 0.81 AURKA (0.47) AURKAAURKBIGF1RRETPLK4
SCHEMBL10123014 0.81 AURKA (0.49) AURKAAURKBIGF1RRETPLK4
SCHEMBL10122964 0.80 AURKA (0.50) AURKAAURKBRIPK1IGF1RAURKC
SCHEMBL10122894 0.79 AURKA (0.69) AURKAAURKBRIPK1IGF1RAURKC
SCHEMBL10122958 0.75 AURKA (0.47) AURKAAURKBIGF1RAURKCRET
SCHEMBL10123046 0.74 ALDH1A1 (0.49) CYP1A2CYP3A4CYP2C9TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114870-B2 Method of treating disease states using substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2012-02-14 US disclosed
US-8114870-B2 Method of treating disease states using substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2012-02-14 US disclosed
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-10-22 US disclosed
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-10-22 US disclosed
US-7563787-B2 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2009-07-21 US disclosed
US-7563787-B2 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2009-07-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
WO-2007041358-A2 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142368-A1 Substituted pyrazole compounds AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885RIPK1 728/4885
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885RIPK1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.